Binimetinib and Encorafenib for the Treatment of Pancreatic Cancer in Patients With a Somatic BRAF V600E Mutation

NCT04390243 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

6

Enrollment

OTHER

Sponsor class

Stopped Slow accrual

Conditions

Locally Advanced Pancreatic Carcinoma
Metastatic Pancreatic Carcinoma
Recurrent Pancreatic Carcinoma
Stage III Pancreatic Cancer AJCC v8
Stage IV Pancreatic Cancer AJCC v8

Interventions

DRUG: Binimetinib
DRUG: Encorafenib

Sponsor

Academic and Community Cancer Research United

Collaborators

[object Object]